AUS
NZ
UK
CA
USA
IND
Highlights
- Opthea pauses trading as it explores funding options
- Clinical trial for OPT-302 misses key target
- Future of wet-AMD treatment strategy under review
Opthea (ASX:OPT) has entered a critical phase in its development journey, as trading of its shares has been temporarily halted for a week. The pause comes after a pivotal clinical trial involving its lead drug candidate, OPT-302, did not achieve the intended outcome, casting uncertainty over the biotech's next steps.
The Melbourne-based company has been conducting a Phase 3 trial investigating the combined use of OPT-302 with Aflibercept—a widely used treatment—to address wet age-related macular degeneration (wet-AMD). Wet-AMD is a progressive eye condition and one of the leading causes of vision loss among people over 50, marked by the growth of abnormal blood vessels in the eye that leads to visual impairment.
The trial aimed to measure improvements in visual acuity, a standard benchmark in ophthalmology to assess the effectiveness of treatment. However, Opthea revealed that the results fell short of meeting the primary endpoint—improvement in vision for patients compared to the current standard.
Following this outcome, Opthea has entered urgent discussions with potential investors and partners to explore strategic options. These talks are focused on securing additional funding and potentially revising the path forward for OPT-302. The company stated that trading would remain suspended for up to a week while these negotiations are underway, giving it time to assess alternatives for the drug program.
The disappointing trial results come at a pivotal moment, as OPT-302 has long been positioned as a complementary treatment to existing therapies like Aflibercept, developed by Regeneron (NASDAQ:REGN). The idea was to enhance patient outcomes by targeting VEGF-C and VEGF-D proteins, in addition to VEGF-A, the pathway Aflibercept focuses on.
While the recent trial outcome introduces fresh challenges, it also opens the door for re-evaluation and potential realignment of the program. The biotech sector, particularly in the high-risk clinical trial phase, often faces such critical moments that can redefine a company's direction.
Opthea has yet to provide a definitive roadmap but is expected to update the market once its current strategic review is complete. Investors and stakeholders will be watching closely for updates in the coming days as the company works to determine the future of its wet-AMD treatment strategy.
